Pharmaceutical Executive: March 2026 Interactive Digital Edition

FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.